Cheyne Capital Management UK LLP acquired a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 18,927 shares of the company’s stock, valued at approximately $555,000. Cheyne Capital Management UK LLP owned […]
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) shares rose 10.1% during mid-day trading on Friday . The stock traded as high as $20.19 and last traded at $20.16. Approximately 29,270 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 94,378 shares. The stock had previously closed at $18.31. […]
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) was the target of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 862,900 shares, a decrease of 7.4% from the March 15th total of 932,200 shares. Based on an average trading volume of 97,500 shares, the […]
Should You Buy or Sell Aerovate Therapeutics Stock? Get The Latest AVTE Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) – Equities researchers at Wedbush boosted their Q1 2023 earnings estimates for Aerovate Therapeutics in a research report issued to clients and investors on Thursday, March 30th. Wedbush analyst A. Argyrides now forecasts that the company will post earnings of ($0.51) per share for the quarter, up from […]